Regeneron nabs dosing edge with Lynozyfic’s FDA approval in multiple myeloma
Regeneron has won US Food and Drug Administration (FDA) approval for Lynozyfic (linvoseltamab-gcpt), marking the entry of another BCMAxCD3 bispecific…
Oncology
-
-
FDA approves Dizal’s Zegfrovy to treat adults with NSCLC
Dizal has received US Food and Drug Administration (FDA) approval for Zegfrovy (sunvozertinib) to treat adults with locally advanced or…
-
Sanofi agrees to invest $25m in Adagene
Sanofi has agreed to invest up to $25m in Adagene, which will enable the latter to fund its research and…
-
Merck concludes SpringWorks acquisition for $3.4bn
Merck KGaA has concluded the previously announced acquisition of SpringWorks Therapeutics for an enterprise value of €3bn ($3.4bn), after receiving…
-
EC approves Jazz Pharmaceuticals’ Ziihera for biliary tract cancer
Jazz Pharmaceuticals has received conditional marketing authorisation from the European Commission (EC) for its new bispecific antibody, Ziihera (zanidatamab), for…
-
Oncternal sells assets for up to $68m and calls it quits
American oncology company Oncternal Therapeutics is to wind down operations after announcing the sale of its main drug programmes. Delaware-based…
-
FDA approves label updates for BMS’ CAR T cell therapies
Bristol Myers Squibb (BMS) has announced that the US Food and Drug Administration (FDA) has given approval to label updates…
-
Porton Advanced and EVA Pharma collaborate for CAR T-cell therapies
Porton Advanced Solutions and EVA Pharma have signed a memorandum of understanding (MoU) to enhance the development and manufacturing capabilities…
-
Gilead eyes Kymera’s ‘adhesive’ cancer drug in $750m deal
Fresh off a regulatory victory for a new HIV product, Gilead is shifting focus to the oncology space – signing…
-
Revolution Medicines partners Royalty Pharma on $2bn funding
Revolution Medicines has partnered Royalty Pharma for $2bn in flexible funding to support the independent worldwide development and commercialisation strategy…
